Literature DB >> 12408788

Myocarditis.

Elaine Winkel1, Joseph Parrillo.   

Abstract

Myocarditis and its sequela, dilated cardiomyopathy (DCM), cause substantial morbidity and mortality, especially in children and young adults. Physicians should include myocarditis in the differential diagnosis of all patients who have new symptoms of heart failure, arrhythmia, or chest pain syndromes of unclear cause, and should strongly consider performing endomyocardial biopsy (EMB) to establish the diagnosis. It may be necessary to perform multiple or serial biopsies to increase sensitivity. Patients with myocarditis and symptomatic heart failure, chest pain, or arrhythmias need hospitalization for evaluation and treatment. Patients with symptomatic left ventricular dysfunction should be treated with conventional heart failure therapy, including angiotensin-converting enzyme (ACE) inhibitors, digitalis, diuretics, and beta-blockers. Patients with arrhythmias or syncope may require electrophysiologic evaluation. In addition to conventional therapy, physicians should consider a course of immunosuppressive therapy in selected patients. The clinical course, response to therapy, and left ventricular function need close monitoring. Patients with myocarditis and rapidly progressive heart failure or cardiogenic shock should be referred early to an advanced heart failure center for implantation of a ventricular assist device and consideration for cardiac transplantation.

Entities:  

Year:  2002        PMID: 12408788     DOI: 10.1007/s11936-002-0040-2

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  27 in total

1.  Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis.

Authors:  R E McCarthy; J P Boehmer; R H Hruban; G M Hutchins; E K Kasper; J M Hare; K L Baughman
Journal:  N Engl J Med       Date:  2000-03-09       Impact factor: 91.245

Review 2.  Molecular aspects of myocarditis.

Authors:  N E Bowles; J A Towbin
Journal:  Curr Opin Cardiol       Date:  1998-05       Impact factor: 2.161

3.  Myocarditis. A histopathologic definition and classification.

Authors:  H T Aretz; M E Billingham; W D Edwards; S M Factor; J T Fallon; J J Fenoglio; E G Olsen; F J Schoen
Journal:  Am J Cardiovasc Pathol       Date:  1987-01

4.  Viral infection of the myocardium in endocardial fibroelastosis. Molecular evidence for the role of mumps virus as an etiologic agent.

Authors:  J Ni; N E Bowles; Y H Kim; G Demmler; D Kearney; J T Bricker; J A Towbin
Journal:  Circulation       Date:  1997-01-07       Impact factor: 29.690

5.  Characterisation of genomic RNA of Coxsackievirus B3 in murine myocarditis: reliability of direct sequencing of reverse transcription-nested polymerase chain reaction products.

Authors:  H Zhang; B Soteriou; S Knowlson; A Theodoridou; L C Archard
Journal:  J Virol Methods       Date:  1997-12       Impact factor: 2.014

6.  Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy.

Authors:  G M Felker; R E Thompson; J M Hare; R H Hruban; D E Clemetson; D L Howard; K L Baughman; E K Kasper
Journal:  N Engl J Med       Date:  2000-04-13       Impact factor: 91.245

Review 7.  Acute infection: metabolic responses, effects on performance, interaction with exercise, and myocarditis.

Authors:  G Friman; N G Ilbäck
Journal:  Int J Sports Med       Date:  1998-07       Impact factor: 3.118

Review 8.  Immunosuppressive and immunomodulatory treatment for myocarditis.

Authors:  B Maisch; M Herzum; G Hufnagel; U Schonian
Journal:  Curr Opin Cardiol       Date:  1996-05       Impact factor: 2.161

9.  Recently diagnosed idiopathic dilated cardiomyopathy: incidence of myocarditis and efficacy of prednisone therapy.

Authors:  R D Latham; J P Mulrow; R Virmani; M Robinowitz; J M Moody
Journal:  Am Heart J       Date:  1989-04       Impact factor: 4.749

10.  Gamma-globulin treatment of acute myocarditis in the pediatric population.

Authors:  N A Drucker; S D Colan; A B Lewis; A S Beiser; D L Wessel; M Takahashi; A L Baker; A R Perez-Atayde; J W Newburger
Journal:  Circulation       Date:  1994-01       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.